Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | RARB | P10826 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | THRA | P10827 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243177 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL15177348 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL9126821 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL7739031 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL9000300 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL10536554 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL9637119 | 1.00 | GAA (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL903877 | 0.98 | L3MBTL1 (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL7732272 | 0.98 | L3MBTL1 (0.77) | GAARARBL3MBTL1TP53TSHR | |
| SCHEMBL762326 | 0.95 | GAA (0.86) | GAARARBL3MBTL1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | GAA 979/4885RARB 4537/4885L3MBTL1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.